{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T07:39:20Z","timestamp":1781163560718,"version":"3.54.1"},"reference-count":143,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2012,1,24]],"date-time":"2012-01-24T00:00:00Z","timestamp":1327363200000},"content-version":"vor","delay-in-days":9822,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[1985,3,4]]},"abstract":"<jats:p>The synthetic aminoacridine derivative amsacrine (m\u2010AMSA) is capable of preventing DNA from serving as a template in replication and DNA synthesis. This mechanism of action is similar to that of anthracyclines, but clinical evidence suggests the lack of cross\u2010resistance. The recommended dosage in patients with solid tumors is 90\u2013120 mg\/m<jats:sup>2<\/jats:sup> intravenously every 3\u20134 weeks. Despite the initial encouraging reports from experimental models, m\u2010AMSA has shown no real impact in the treatment of patients with a wide variety of solid tumors. In relapsed acute nonlymphocytic leukemia, 20\u201330% of patients will achieve complete remission. An increased remission rate is obtained when m\u2010AMSA is combined with other agents, especially with high\u2010dose cytosine arabinoside, with a complete remission rate of 50\u201360% in relapsed patients. Currently, several phase III trials are evaluating m\u2010AMSA combinations against daunorubicin\u2010containing regimens in patients with previously untreated acute leukemia. The potential role of these regimens in this disease remains to be defined.<\/jats:p>","DOI":"10.1002\/j.1875-9114.1985.tb03406.x","type":"journal-article","created":{"date-parts":[[2015,12,16]],"date-time":"2015-12-16T20:01:09Z","timestamp":1450296069000},"page":"78-90","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Amsacrine (m\u2010AMSA): A New Antineoplastic Agent Pharmacology, Clinical Activity and Toxicity"],"prefix":"10.1002","volume":"5","author":[{"given":"Javier","family":"Hornedo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Van Echo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,24]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00276a011"},{"key":"e_1_2_1_3_2","first-page":"1421","article-title":"Phase I study of methanesulfonamide, N\u2010[4\u20139\u2010acridinylamino)\u20103\u2010methoxyphenl]\u2010(m\u2010AMSA) using a single\u2010dose schedule","volume":"62","author":"Hoff DD","year":"1978","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_4_2","first-page":"23","article-title":"Randomized bioequivalency study of DMA\/lactic acid and gluconate formulations of amsacrine","volume":"1","author":"Knutsen C","year":"1982","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1977.tb21984.x"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/60.5.1147"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/60.5.1155"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2964(76)90066-9"},{"key":"e_1_2_1_9_2","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/0006-291X(79)90223-7","article-title":"Interaction of antitumor drugs with human erythrocyte ghost membranes and mastocytoma P815: a spin label study","volume":"86","author":"Sinha BK","year":"1979","journal-title":"Biochem Biophys Res Commun"},{"key":"e_1_2_1_10_2","first-page":"1535","article-title":"In vivo characteristics of resistance and cross\u2010resistance of an Adriamycin\u2010resistant subline of P388 leukemia","volume":"62","author":"Johnson RK","year":"1978","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_11_2","first-page":"163","article-title":"Antiviral activity of 4\u2032\u2010(9\u2010acridinylamino)\u2010methane\u2010sulphon\u2010m\u2010anisidide (SN11841)","volume":"18","author":"Byrd DM.","year":"1977","journal-title":"Ann NY Acad Sci"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.897680"},{"key":"e_1_2_1_13_2","first-page":"3881","article-title":"Phase I clinical and pharmacological study 4\u2032\u2010(9\u2010acridinylamino) methane\u2010sulphon\u2010m\u2010anisidide using an intermittent biweekly schedule","volume":"39","author":"Echo DA","year":"1979","journal-title":"Cancer Res"},{"key":"e_1_2_1_14_2","first-page":"175","article-title":"Clinical pharmacokinetics of the new antitumor agent AMSA","volume":"20","author":"Hall SW","year":"1979","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_2_1_15_2","first-page":"198","article-title":"Pharmacokinetics of m\u2010AMSA (NSC 249992) in humans","volume":"20","author":"Staubus A","year":"1980","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_2_1_16_2","first-page":"429","article-title":"Phase I study of oral 4\u2032\u2010(9\u2010acridinylamino)\u2010methanesulphon\u2010m\u2010anisidide (m\u2010AMSA NSC 249992)","volume":"20","author":"DeJager R","year":"1979","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_17_2","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0090-9556(25)05971-9","article-title":"The pharmacologic disposition of 4\u2032\u2010(9\u2010acridinyl\u2010amino)\u2010methanesulphon\u2010m\u2010anisidide in mice and rats","volume":"5","author":"Cysyk RL","year":"1979","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_1_18_2","first-page":"17","article-title":"Tissue distribution of AMSA in patients","volume":"1","author":"Savaraj N","year":"1982","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_19_2","volume-title":"m\u2010AMSA (NSC 249992) group C protocol for the therapy of refractory adult acute myelogenous leukemia with m\u2010AMSA given as a single agent","author":"Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment, National Cancer Institute.","year":"1982"},{"key":"e_1_2_1_20_2","first-page":"17","article-title":"Tumor penetration of AMSA in man","volume":"1","author":"Zhengang G","year":"1982","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_21_2","first-page":"539","article-title":"The experimental antitumor properties of three congeners of the acridylmethanesulphonanilide (AMSA) series. Europ. J","volume":"10","author":"Cain BF","year":"1974","journal-title":"Cancer"},{"key":"e_1_2_1_22_2","first-page":"1610","volume-title":"Current chemotherapy and infectious disease","author":"Sordillo P","year":"1980"},{"issue":"5","key":"e_1_2_1_23_2","first-page":"640","article-title":"Chemotherapy of human colon xenografts in athymic nude mice","volume":"40","author":"Osieka R","year":"1977","journal-title":"Cancer"},{"key":"e_1_2_1_24_2","first-page":"53","article-title":"Phase I evaluation of 4\u2032\u2010(9\u2010acridinylamino)\u2010methanesulphon\u2010m\u2010anisidide (AMSA) by a weekly IV dose schedule","volume":"64","author":"Woodcock TM","year":"1980","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_25_2","first-page":"1354","article-title":"Quantitative prediction of drug toxicity in humans from toxicology in small and large animals","volume":"35","author":"Goldsmith MA","year":"1975","journal-title":"Cancer Res"},{"key":"e_1_2_1_26_2","first-page":"3712","article-title":"Phase I clinical investigation of 4\u2032\u2010(9\u2010acridinylamino)\u2010methanesulphon\u2010m\u2010anisidide (NSC 249992), a new acridine derivative","volume":"38","author":"Legha SS","year":"1978","journal-title":"Cancer Res"},{"key":"e_1_2_1_27_2","first-page":"128","article-title":"Early clinical evaluation of 4\u2032\u20109\u2010acridinylamino)\u2010methanesulphon\u2010m\u2010anisidide (AMSA) in patients with advanced breast cancer and acute leukemia","volume":"20","author":"Legha SS","year":"1979","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_28_2","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1182\/blood.V60.2.484.484","article-title":"Evaluation of AMSA in previously treated patients with acute leukemia: results of therapy in 109 adults","volume":"60","author":"Legha SS","year":"1982","journal-title":"Blood"},{"key":"e_1_2_1_29_2","first-page":"3304","article-title":"Phase I and II trial of 4\u2032\u2010(9\u2010acridinylamino)\u2010methanesulphon\u2010m\u2010anisidide in patients with acute leukemia","volume":"40","author":"Arlin ZA","year":"1980","journal-title":"Cancer Res"},{"key":"e_1_2_1_30_2","first-page":"285","article-title":"A phase I\u2010II study of m\u2010AMSA in acute leukemia","volume":"44","author":"Slevin ML","year":"1981","journal-title":"Br J Cancer"},{"key":"e_1_2_1_31_2","first-page":"477","article-title":"A phase II trial of m\u2010AMSA in acute leukemia","volume":"22","author":"Dupont J","year":"1981","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_32_2","first-page":"1475","article-title":"AMSA: a promising new agent in refractory acute leukemia","volume":"66","author":"Lawrence HJ","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_33_2","first-page":"230","article-title":"A phase II trial of 4\u2032\u2010(9\u2010acridinylamino)\u2010methanesulphon\u2010m\u2010anisidide (AMSA) in adult relapsed acute leukemia","volume":"22","author":"Echo DA","year":"1981","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_2_1_34_2","first-page":"112","article-title":"Phase II study of amsacrine (m\u2010AMSA) gluconate in refractory adult acute leukemia","volume":"23","author":"Omura GA","year":"1982","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_2_1_35_2","first-page":"537","volume-title":"Third international symposium on therapy of acute leukemias","author":"Jackson JM","year":"1982"},{"key":"e_1_2_1_36_2","first-page":"173","article-title":"High\u2010dose cytosine arabinoside (ARA\u2010C) and m\u2010AMSA in relapsed acute non\u2010lymphocytic leukemia (ANLL)","volume":"2","author":"Hines JD","year":"1983","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_37_2","first-page":"317","article-title":"Treatment of acute leukemia with 4\u2032\u2010(9\u2010acridinylamino)\u2010methanesulphon\u2010m\u2010anisidide (AMSA) in combination with cytosine arabinoside and thioguanine","volume":"4","author":"Arlin ZA","year":"1981","journal-title":"Cancer Clin Trials"},{"key":"e_1_2_1_38_2","first-page":"142a","article-title":"4\u2032\u2010(9\u2010acridinylamino)\u2010methanesulphon\u2010m\u2010anisidide (AMSA), VP\u201016\u2013213 (VP), cytosine arabinoside (ARA\u2010cO) and 6\u2010thioguinine (6TG) in the treatment of relapsed and refractory acute nonlymphocytic leukemia (ANLL)","volume":"58","author":"Hurd DD","year":"1981","journal-title":"Blood"},{"key":"e_1_2_1_39_2","first-page":"479","article-title":"Use of a 4\u2032\u2010(9\u2010acridinylamino)\u2010methanesulphon\u2010m\u2010anisidide (AMSA), cytosine\u2010arabinoside (ARA\u2010C), vincristine, prednisone combination (AMSA\u2010OAP) in poor\u2010risk patients with acute leukemia","volume":"22","author":"McCredie KB","year":"1981","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198308000-00018"},{"key":"e_1_2_1_41_2","first-page":"174","article-title":"Phase\u2010I\u2010II study of 5\u2010azacytidine (NSC 102816) and amsacrine (AMSA) (NSC 249992) in refractory adult acute leukemia","volume":"2","author":"Winton EF","year":"1983","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_42_2","first-page":"172","article-title":"Phase II study of combination of 4\u2032\u2010(9\u2010acridinylamino)\u2010methanesulphon\u2010m\u2010anisidide (AMSA) and cis\u2010platinum diammine\u2010dichloride (CPDD) in the treatment of adult acute leukemia (AAL)","volume":"2","author":"Chwala S","year":"1983","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_43_2","first-page":"967","article-title":"Current status of amsacrine (AMSA) combination chemotherapy programs in acute leukemia","volume":"67","author":"Arlin ZA.","year":"1983","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_44_2","first-page":"127","article-title":"A method for evaluation of novel therapy in previously untreated patients: AMSA\u2010OAP combination therapy in adult leukemia","volume":"23","author":"Freireich EJ","year":"1982","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_45_2","first-page":"189","article-title":"High\u2010dose cytosine arabinoside (HD ARA\u2010C) and m\u2010AMSA induction and consolidation in acute nonlymphocytic leukemia","volume":"3","author":"Hines JD","year":"1984","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/55.6.1265"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1971124599"},{"key":"e_1_2_1_48_2","first-page":"1863","article-title":"Fatal hepatoxicity associated with AMSA therapy","volume":"66","author":"Appelbaum FR","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V62.2.361.361"},{"key":"e_1_2_1_50_2","first-page":"655","article-title":"Phase II study of AMSA in lung cancer","volume":"65","author":"Samson MK","year":"1981","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_51_2","first-page":"367","article-title":"Phase II study of 4\u2032\u2010(9\u2010acridinylamino)\u2010methanesulphon\u2010m\u2010anisidide (m\u2010AMSA, NSC 249992)","volume":"22","author":"DeJager R","year":"1981","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_52_2","first-page":"1383","article-title":"Phase II evaluation of AMSA in patients with metastatic lung cancer","volume":"64","author":"Nichols WC","year":"1980","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_53_2","first-page":"345","article-title":"A phase II evaluation of 4\u2032\u2010(9\u2010acridinylamino)\u2010methanesulphon\u2010m\u2010anisidide (AMSA) in patients with non\u2010small cell lung cancer","volume":"64","author":"Casper ES","year":"1980","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198304000-00004"},{"key":"e_1_2_1_55_2","first-page":"133","article-title":"Phase II trial of AMSA in patients with refractory small cell carcinoma of the lung","volume":"65","author":"Fuks JZ","year":"1981","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_56_2","first-page":"393","article-title":"A phase II trial of m\u2010AMSA in patients with small cell lung cancer","volume":"4","author":"Natale RB","year":"1981","journal-title":"Cancer Clin Trials"},{"key":"e_1_2_1_57_2","first-page":"403","article-title":"Phase II trial of AMSA in refractory breast cancer","volume":"66","author":"Lena M","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_58_2","first-page":"1961","article-title":"Phase II study of 4\u2032\u2010(9\u2010acridinylamino)\u2010methanesulphon\u2010m\u2010anisidide (AMSA) in metastatic breast cancer","volume":"63","author":"Legha SS","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_59_2","first-page":"249","article-title":"A phase II evaluation of 4\u2032\u2010(9\u2010acridinylamino)\u2010methanesulphon\u2010m\u2010anisidide in patients with metastatic breast cancer","volume":"4","author":"Currie VE","year":"1981","journal-title":"Cancer Clin Trials"},{"key":"e_1_2_1_60_2","first-page":"1211","article-title":"Phase II study of AMSA in patients with metastatic breast cancer: a cancer and leukemia group B study","volume":"66","author":"Amrein PC","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_61_2","first-page":"1235","article-title":"Phase II study of AMSA, predinsone and chlorambucil (APC) in the treatment of refractory breast cancer: a Northern California Oncology Group study","volume":"66","author":"Friedman MA","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_62_2","first-page":"599","article-title":"Phase II study of high\u2010dose amsacrine (AMSA) and autologous bone marrow transplantation in patients with refractory metastatic breast cancer","volume":"67","author":"Tannir N","year":"1983","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_63_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198302000-00006"},{"key":"e_1_2_1_64_2","first-page":"345","article-title":"Treatment of advanced colorectal carcinoma with AMSA","volume":"65","author":"Ferraro JA","year":"1981","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_65_2","first-page":"474","article-title":"m\u2010AMSA in the treatment of advanced colorectal, pancreatic, and gastric carcinoma","volume":"22","author":"Lessner HE","year":"1981","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_66_2","first-page":"1149","article-title":"Phase II evaluation of 4\u2032\u2010(9\u2010acridinylamino)\u2010methanesulphon\u2010m\u2010anisidide (AMSA) in patients with advanced colorectal carcinoma","volume":"64","author":"Carroll DS","year":"1980","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_67_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198206000-00006"},{"key":"e_1_2_1_68_2","first-page":"100","article-title":"A phase II evaluation of m\u2010AMSA in advanced gastric and pancreatic carcinoma, a SWOG study","volume":"1","author":"Inamasu M","year":"1982","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_69_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198308000-00011"},{"key":"e_1_2_1_70_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198304000-00013"},{"key":"e_1_2_1_71_2","first-page":"91","article-title":"Treatment of advanced malignant hepatoma with Adriamycin or AMSA in combination with VM\u201026 + 5FU","volume":"1","author":"Bezwoda WR","year":"1982","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_72_2","first-page":"1651","article-title":"Phase II trial of m\u2010AMSA in hepatocellular carcinoma: a SWOG study","volume":"66","author":"Bukowski RM","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_73_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00262329"},{"key":"e_1_2_1_74_2","first-page":"550","article-title":"A phase II\u2010III trial of neocarzinostatin versus m\u2010AMSA or Adriamycin in hepatocellular carcinoma: an ECOG study","volume":"23","author":"Falkson G","year":"1983","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_2_1_75_2","first-page":"1009","article-title":"A phase II trial of 4\u2032\u2010(9\u2010acridinylamino)\u2010methanesulphon\u2010m\u2010anisidide (AMSA) in patients with metastatic renal cell carcinoma","volume":"64","author":"Echo DA","year":"1980","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_76_2","first-page":"183","article-title":"Phase II trial of 44\u2032\u2010(9\u2010acridinylamino)\u2010methanesulphon\u2010m\u2010anisidide (AMSA) in patients with metastatic hypernephroma","volume":"64","author":"Schneider RJ","year":"1980","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_77_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198310000-00008"},{"key":"e_1_2_1_78_2","first-page":"105","article-title":"Combination of cyclophosphamide, Adriamycin and cisplatinum (CAP) versus m\u2010AMSA in patients with advanced transitional bladder cancer","volume":"1","author":"Al\u2010Sarraf M.","year":"1982","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_79_2","first-page":"391","article-title":"Phase II trial of amsacrine (AMSA) in urinary bladder cancer","volume":"67","author":"Natale RB","year":"1983","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_80_2","first-page":"208","article-title":"Phase II trial of AMSA in prostatic cancer","volume":"66","author":"Natale RB","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_81_2","first-page":"464","article-title":"Clinical trial of m\u2010AMSA in patients with advanced prostate carcinoma \u2014 phase II","volume":"22","author":"Drelichman A","year":"1981","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_82_2","first-page":"309","article-title":"A phase II study of AMSA in refractory testicular cancer","volume":"67","author":"Williams SD","year":"1983","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_83_2","first-page":"526","article-title":"Evaluation of m\u2010AMSA (NSC\u2010249992) in the treatment of advanced head and neck cancer. Phase II study","volume":"22","author":"Ratanatharathorn S","year":"1981","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_84_2","first-page":"435","article-title":"Phase II trial of amsacrine in metastatic or locally recurrent squamous cell carcinoma from the head and neck primaries: a SWOG study","volume":"68","author":"Witherspoon RP","year":"1984","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_85_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00262333"},{"key":"e_1_2_1_86_2","first-page":"1589","article-title":"Phase II trial of AMSA in previously treated patients with stage II and IV ovarian cancer","volume":"66","author":"Schneider RJ","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_87_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1479-828X.1982.tb01416.x"},{"key":"e_1_2_1_88_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198306000-00004"},{"key":"e_1_2_1_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(82)90027-X"},{"key":"e_1_2_1_90_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198206000-00010"},{"key":"e_1_2_1_91_2","unstructured":"RetsasS VonHoffDD NewtonKA WestburyG.Evaluation of m\u2010AMSA in advanced malignant melanoma. Presented at the twelth international conference of chemotherapy Florence Italy;1981."},{"key":"e_1_2_1_92_2","first-page":"1237","article-title":"Phase II evaluation of AMSA in patients with stage III\u2010IV malignant melanoma","volume":"66","author":"Fuks JZ","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_93_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198208000-00015"},{"key":"e_1_2_1_94_2","first-page":"170","article-title":"Phase II study of AMSA in patients with metastatic malignant melanoma","volume":"65","author":"Houghton AN","year":"1981","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_95_2","first-page":"169","article-title":"Phase II evaluation of PALA and AMSA for patients with disseminated malignant melanoma","volume":"65","author":"Creagan ET","year":"1981","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_96_2","first-page":"372","article-title":"AMSA: a new acridine derivative with activity against metastatic melanoma","volume":"20","author":"Hall JW","year":"1979","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_97_2","first-page":"341","article-title":"Phase II evaluation of AMSA in adult sarcomas","volume":"65","author":"Yap BS","year":"1981","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_98_2","first-page":"489","article-title":"Phase II study of amsacrine (m\u2010AMSA) in advanced lymphomas: a Southwest Oncology Group study","volume":"67","author":"Weick JK","year":"1983","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_99_2","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1182\/blood.V57.3.614.614","article-title":"Initial experience with AMSA as a single\u2010agent treatment against malignant lymphoproliferative disorders","volume":"57","author":"Cabanillas F","year":"1981","journal-title":"Blood"},{"key":"e_1_2_1_100_2","first-page":"1157","article-title":"Phase II trial of 4\u2032\u2010(9\u2010acridinylamino)\u2010methanesulphon\u2010m\u2010anisidide (AMSA) in the treatment of advanced non\u2010Hodgkin's lymphoma","volume":"64","author":"Warrell RP","year":"1980","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_101_2","first-page":"211","article-title":"Intensive chemotherapy with cyclophosphamide (C), m\u2010AMSA (AM) and VP\u201016 (CAMP) as treatment for refractory and relapsing non\u2010Hodgkin's lymphoma (NHL)","volume":"2","author":"Berkman A","year":"1983","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_102_2","unstructured":"CabanillasF.Results with amsacrine in the treatment of refractory lymphomas. In:Amsacrine: current perspectives and clinical results with a new anticancer agent. Proceedings of an International Symposium on AMSA Nice France April 3 1982."},{"key":"e_1_2_1_103_2","first-page":"320","article-title":"Amsacrine (AMSA) in the treatment of lymphoma","volume":"67","author":"Warrell RP.","year":"1983","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_104_2","unstructured":"MarlarmeM BrowD DelforgeA.Combination of high\u2010dose BCNU and m\u2010AMSA followed by autologous bone marrow transplantination (BAM). Presented at the sixth meeting of the International Society of Hematology European and African divdision Athens Greece 1981."},{"key":"e_1_2_1_105_2","first-page":"385","article-title":"High\u2010dose AMSA and bone marrow rescue in patients with solid tumors","volume":"66","author":"Zander AR","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_106_2","first-page":"1579","article-title":"Phase II study of 4\u2032\u2010(9\u2010acridinylamino)\u2010methanesulphon\u2010m\u2010anisidide (NSC 249992) in children with acute leukemia and lymphoma","volume":"42","author":"Tan CTC","year":"1982","journal-title":"Cancer Res"},{"key":"e_1_2_1_107_2","first-page":"4250","article-title":"Phase I clinical and pharmacokinetic study of 4\u2032\u2010(9\u2010acridinylamino)\u2010methanesulphon\u2010m\u2010anisidide in children with cancer","volume":"40","author":"Rivera G","year":"1980","journal-title":"Cancer Res"},{"key":"e_1_2_1_108_2","first-page":"403","article-title":"Efficacy and toxicity of 4\u2032\u2010(9\u2010acridinylamino) (249992) methenensulfon\u2010m\u2010anisidide, (m\u2010AMSA) in advanced childhood leukemia","volume":"22","author":"Land VJ","year":"1981","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_109_2","first-page":"593","article-title":"AMSA therapy for children with lymphoblastic malignancy","volume":"66","author":"Hutter JJ","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_110_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00296763"},{"key":"e_1_2_1_111_2","first-page":"119","article-title":"4\u2032\u2010(9\u2010acridinylamino)\u2010methanesulphon\u2010m\u2010anisidide (AMSA) \u2014 cyclocytidine (Cyclo) in children with acute leukemia","volume":"23","author":"Miller L","year":"1982","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_2_1_112_2","first-page":"178","article-title":"m\u2010AMSA activity in pediatric solid tumors","volume":"1","author":"Civin CI","year":"1982","journal-title":"Am Soc Clin Oncol"},{"key":"e_1_2_1_113_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-93-1-17"},{"key":"e_1_2_1_114_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2964(81)90018-9"},{"key":"e_1_2_1_115_2","first-page":"2001","article-title":"Neurologic and cardiac rhythm abnormalities associated with 4\u2032\u2010(9\u2010acridinylamino)\u2010methanesulphon\u2010m\u2010anisidide (AMSA) therapy","volume":"63","author":"Legha SS","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_116_2","first-page":"102","article-title":"AMSA\u2010induced seizures in patients with hypokalemia","volume":"67","author":"Mittelman A","year":"1983","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_117_2","volume-title":"Preclinical toxicologic evaluation of 4\u2032\u2010(9\u2010acridinylamino)\u2010methanesulphon\u2010m\u2010anisidide monochloride in mice, dogs and monkeys","author":"Henry MC","year":"1976"},{"key":"e_1_2_1_118_2","first-page":"320","article-title":"Review of amsacrine, an investigational antineoplastic agent","volume":"1","author":"Grove WR","year":"1982","journal-title":"Clin Pharm"},{"key":"e_1_2_1_119_2","first-page":"356","article-title":"Acute ventricular fibrillation and death during infusion of 4\u2032\u2010(9\u2010acridinylamino)\u2010methanesulphon\u2010m\u2010anisidide (AMSA)","volume":"64","author":"Hoff DD","year":"1980","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_120_2","first-page":"358","article-title":"Multiple ventricular extrasystoles following administration of 4\u2032\u2010(9\u2010acridinylamino)\u2010methanesulphon\u2010m\u2010anisidide (AMSA)","volume":"64","author":"Falkson G.","year":"1980","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_121_2","first-page":"183","article-title":"Cardiotoxicity associated with amsacrine","volume":"2","author":"Grillo\u2010Lopez AJ","year":"1983","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_122_2","first-page":"1599","volume-title":"The heart","author":"Fisch C.","year":"1982"},{"key":"e_1_2_1_123_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19830801)52:3<557::AID-CNCR2820520329>3.0.CO;2-M"},{"key":"e_1_2_1_124_2","first-page":"1169","article-title":"Acute electrocardiographic changes induced by amsacrine","volume":"68","author":"Shinar E","year":"1984","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_125_2","first-page":"483","article-title":"Cardiac abnormalities after AMSA administration","volume":"66","author":"Steinherz LJ","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_126_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(77)90315-1"},{"key":"e_1_2_1_127_2","first-page":"1381","article-title":"Age\u2010related Adriamycin cardiotoxicity in children","volume":"62","author":"Pratt CB","year":"1978","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_128_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-91-5-710"},{"key":"e_1_2_1_129_2","first-page":"271","article-title":"Extravasation of vesicant antineoplastics: clinical and experimental findings","volume":"38","author":"Dorr RT.","year":"1981","journal-title":"Ariz Med"},{"key":"e_1_2_1_130_2","first-page":"919","article-title":"Allergic reactions following administration of AMSA","volume":"65","author":"Welt S","year":"1981","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_131_2","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1182\/blood.V60.2.484.484","article-title":"Evaluation of AMSA in previously treated patients with acute leukemia: results of therapy in 109 adults","volume":"60","author":"Legha SS","year":"1982","journal-title":"Blood"},{"key":"e_1_2_1_132_2","first-page":"3304","article-title":"Phase I and II trial of 4\u2032\u2010(9\u2010acridinylamino)\u2010methanesulphon\u2010m\u2010anisidide in patients with acute leukemia","volume":"40","author":"Arlin ZA","year":"1980","journal-title":"Cancer Res"},{"key":"e_1_2_1_133_2","first-page":"1475","article-title":"AMSA: a promising new agent in refractory acute leukemia","volume":"66","author":"Lawrence HJ","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_134_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2964(80)90198-X"},{"key":"e_1_2_1_135_2","first-page":"173","article-title":"High dose cytosine arabinoside (ara\u2010C) and m\u2010AMSA in relapsed acute non\u2010lymphocytic leukemia (ANLL)","volume":"2","author":"Hines JD","year":"1983","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_136_2","first-page":"967","article-title":"Current status of amsacrine (AMSA) combination chemotherapy programs in acute leukemia","volume":"67","author":"Arlin ZA","year":"1983","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_137_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-93-1-17"},{"key":"e_1_2_1_138_2","first-page":"1863","article-title":"Fatal hepatoxicity associated with AMSA therapy","volume":"66","author":"Appelbaum FR","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_139_2","first-page":"C","article-title":"Cardiotoxicity associated with amsacrine","volume":"2","author":"Grillo\u2010Lopez AJ","year":"1983","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_140_2","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1182\/blood.V60.2.484.484","article-title":"Evaluation of AMSA in previously treated patients with acute leukemia: Results of therapy in 109 adults","volume":"60","author":"Legha SS","year":"1982","journal-title":"Blood"},{"key":"e_1_2_1_141_2","first-page":"173","article-title":"High dose cytosine arabinoside (ARA\u2010C) and m\u2010AMSA in relapsed acute non\u2010lymphocytic leukemia (ANLL) (abstract)","volume":"2","author":"Hines JD","year":"1983","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_142_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V62.2.361.361"},{"key":"e_1_2_1_143_2","first-page":"967","article-title":"Current status of amsacrine (AMSA) combination chemotherapy programs in acute leukemia","volume":"67","author":"Arlin ZA.","year":"1983","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_144_2","first-page":"1863","article-title":"Fatal hepatotoxicity associated with AMSA therapy","volume":"66","author":"Appelbaum FR","year":"1982","journal-title":"Cancer Treat Rep"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1875-9114.1985.tb03406.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1875-9114.1985.tb03406.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/j.1875-9114.1985.tb03406.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:06:23Z","timestamp":1761044783000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/j.1875-9114.1985.tb03406.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1985,3,4]]},"references-count":143,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1985,3,4]]}},"alternative-id":["10.1002\/j.1875-9114.1985.tb03406.x"],"URL":"https:\/\/doi.org\/10.1002\/j.1875-9114.1985.tb03406.x","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[1985,3,4]]},"assertion":[{"value":"2012-01-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}